<i>SLCO1B1</i> and <i>ABCB1</i> variants synergistically influence the atorvastatin treatment response in South Indian coronary artery disease patients-Reference-Cited by-同舟云学术

SLCO1B1 and ABCB1 variants synergistically influence the atorvastatin treatment response in South Indian coronary artery disease patients

Published:2022-08 Issue:12 Volume:23 Page:683-694
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Bharath Govindaswamy¹,Vishnuprabu Durairaj Pandian¹²,Preethi Loganathan¹³,Nagappan Arumugam Suriyam³,Dhianeshwaran Isravanya Ramia Thiagaraja⁴,Bhaskar Lakkakula VKS⁵,Swaminathan Nagarajan⁶,Munirajan Arasambattu Kannan¹³^ORCID

Affiliation:

1. Department of Genetics, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

2. Center for Vascular and Inflammatory Disease, University of Maryland Baltimore, School of Medicine, Baltimore, MD 21201, USA

3. Department of Health Research Multi-Disciplinary Research Unit, Dr ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, 600113, India

4. Department of Pharmacology, Madras Medical College, Chennai, Tamil Nadu, 600003, India

5. Department of Life Sciences, Guru Ghasidas University, Bilaspur, Chhattisgarh, 495009, India

6. Institute of Cardiology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, 600003, India

Abstract

Introduction: Atorvastatin exhibits wide interindividual variability in treatment response, limiting the drug efficacy in coronary artery disease patients. Aim: To study the effect of genetic variants involved in atorvastatin transport/metabolism and correlate their lipid-lowering efficacy. Materials & methods: Genotyping was performed using 5′-hydrolysis probe method (n = 412), and the study evaluated the treatment response in 86 patients. Results: Significant reduction in total cholesterol and low-density lipoprotein cholesterol (LDL-C) were observed in SLCO1B1-rs4149056, rs4363657 and ABCB1-rs1045642 genotypes. The combined genotypes of ABCB1 and SLCO1B1 showed a strong synergistic effect in reducing the total cholesterol and LDL-C. Diabetes and smoking were observed to influence the LDL-C reduction. Conclusion: The genetic variants of SLCO1B1 and ABCB1 predict the lipid-lowering efficacy of atorvastatin, and this may be useful in genotype-guided statin therapy for coronary artery disease patients.

Funder

Indian Council of Medical Research

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2022-0044

Reference38 articles.

1. Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol

2. Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes

3. Safety and efficacy of statin therapy

4. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction